



# Perfusion media development for scalable processes



Patrick Mayrhofer<sup>1\*</sup>, Andreas Castan<sup>2</sup>, Renate Kunert<sup>1</sup>

<sup>1</sup>University of Natural Resources and Life Sciences (BOKU), Vienna, Muthgasse 11, 1190 Vienna, Austria

<sup>2</sup>GE Healthcare Bio-Sciences AB, Björkgatan 30, 75184 Uppsala, Sweden

\*patrick.mayrhofer@boku.ac.

## Abstract

Cell culture perfusion processes are considered optimal for a truly integrated continuous biomanufacturing pipeline. The nutrient-rich but balanced media should be designed to support very low cell-specific perfusion rates (CSPR) that minimize media consumption while maximizing viable cell days and productivities. Optimized processes at low CSPR drastically reduce equipment costs, lab space, and product dilution. Finally, operating at very low CSPR will allow for mammalian cell bioprocesses to run as true chemostat cultures in the future.

In this study, we demonstrate a general workflow to develop high-performing perfusion media using small-scale models and transfer the process to a 50 L scale at CSPR of 20 pL/cell/d.

## Materials and methods

**Cell line:** HyClone™ Chinese hamster ovary (CHO) cells (CHO-K1, IgG1)

**Basal media:** HyClone CDM4NS0 or Hyclone ActiPro™

**Feed supplements:** see Figure 1

**Analytical methods:** Vi-CELL™ (viable cell density [VCD]), BioProfile™ 100 plus (glucose, lactate, glutamine, glutamate, NH4+), Osmomat 030 (mOsm/kg), Octet™ QK (titer)

**Design of Experiment (DoE, Steps 1 and 2)**

Three DoE levels (-1, 0, +1)

- Level -1: translates into 0% spike concentration
- Level 0: half-maximum spike concentrations
- Level +1: all Cell Boost™ supplements were mixed according to total amino acid concentration and spiked into basal media to reach 400 mOsm/kg; design of DoE matrix and establishment of final statistical models were performed using MODDE™ software

**Semi-continuous small-scale perfusion models (Steps 2 and 3)**

Start VCD:  $10 \times 10^6$  cells/mL in 10 mL (spiked) basal medium

One volume exchange per day (1 reactor volume [RV]/d) by centrifugation at 300 g/7 min after bleeding if applicable

220 rpm at 50 mm shaking diameter in a Kuhnner shaker instrument at 7% CO<sub>2</sub> and 85% humidity at 37°C

**Bioreactor verification runs (Step 4)**

Optimized CDM4NS0 or ActiPro perfusion medium was applied to perfusion bioreactors using a ReadyToProcess WAVE™ 25 or Xcellerex™ XDR 50 bioreactor; cells seeded at  $1 \times 10^6$  cells/mL in unspiked basal medium, and perfusion initiated on days 2 to 4 at a working volume of 500 mL or 40 L; culture parameters set to control > 30% dissolved oxygen (DO), 37°C, pH 6.8 to 7.0

| Cell Boost supplement | Stock conc. [w/w] | Amino acids | Vitamins | Glucose | Trace elements | Growth factors (peptides) | Hypoxanthine/Thymidine | ADCF lipids | ADCF cholesterol |
|-----------------------|-------------------|-------------|----------|---------|----------------|---------------------------|------------------------|-------------|------------------|
| 1                     | 10%               | •           | •        | •       |                |                           |                        |             |                  |
| 2                     | 10%               | •           |          | •       |                |                           |                        |             |                  |
| 3                     | 5%                | •           | •        | •       | •              |                           | •                      |             |                  |
| 4                     | 10%               | •           | •        | •       | •              | •                         |                        | •           | •                |
| 5                     | 5%                | •           | •        | •       | •              | •                         | •                      | •           | •                |
| 6                     | 5%                | •           | •        | •       | •              | •                         | •                      | •           | •                |
| 7a                    | 18.1%             | •           | •        | •       | •              |                           |                        |             |                  |
| 7b                    | 9.5%              | •           |          |         |                |                           |                        |             |                  |

Fig 1. HyClone Cell Boost supplements for development of high-performing perfusion media. ADCF = animal-derived component-free.

## Results

A generally applicable perfusion medium development workflow was applied to two different HyClone CHO basal media: ActiPro and CDM4NS0. In a first screening round (Fig 2, step 1) beneficial effects of Cell Boost supplements 1, 3, 7a, and 7b were identified using a DoE approach in spiked batch cultures. The pre-selected supplements were subsequently applied to a second DoE using 10 mL shaking cultures in a semi-continuous perfusion mode by daily media exchange (Fig 2, step 2), where the primary objective was to fine-tune the ratio of pre-selected Cell Boost supplements. High VCDs of more than  $50 \times 10^6$  cells/mL in a quasi steady-state were reached. Spiking basal medium with Cell Boost supplements improved viabilities and daily titers, with values up to 1 g/L. Subsequent bleeding experiments in semi-perfusion cultures (Fig 2, step 3) revealed higher maintained growth rates at higher bleeding rates, correlating with higher specific productivities. Despite lower steady-state VCDs, increased specific productivity resulted in the titer increasing by 20% when a 30%




Fig 2. Fast workflow for perfusion media development. After initial definition of optimal basal media, eight different Cell Boost supplements were screened, optimized, and tested in four consecutive steps using DoE and small-scale semi-continuous perfusion models.




Fig 3. DoE 2 optimization of pre-selected Cell Boost supplements in small-scale semi-continuous perfusion models (Step 2). Regression analysis was performed to define the final perfusion models.




Fig 4. Effect of daily cell bleed (Step 3). Semi-perfusion cultures were bled daily at 20% to 40% before each media exchange.

## Conclusion

- A DoE-based workflow was developed to leverage established feed supplements for definition of novel, high-performing perfusion media.
- Small-scale models in semi-continuous perfusion mode were used to screen different conditions within a single operator.
- A minimum CSPR of 10 pL/cell/d was determined by constant volumetric perfusion rates in a ReadyToProcess WAVE 25 bioreactor to reach  $200 \times 10^6$  cells/mL.
- A steady-state production perfusion run was scaled up to an Xcellerex XDR 50 L bioreactor.
- Glycosylation increased in galactosylated species in bioreactor perfusion runs but decreased in the semi-continuous models, likely due to higher amounts of ammonia accumulation.
- Critical culture parameters were very similar between bled small-scale cultures and the perfusion bioreactor at similar CSPRs.

